GlassScriptPhysician profile
Lisa J Baker
NPI 1912389503
$8,907.05
in general payments reported to CMS, 2019-2025
22 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,414 · 2022: $1,481 · 2023: $2,250 · 2024: $1,975 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,007 · Education: $5.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,006.96 |
| Education | $5.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,452.17 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $1,094.68 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $984.30 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $863.70 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $793.01 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $621.79 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $580.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $435.24 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $426.39 | 2021-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $363.57 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $261.97 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $193.93 | 2024-2025 | Cobenfy |
| Indivior INC. | $191.44 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $135.28 | 2021-2023 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $131.06 | 2022-2024 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $94.31 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $83.78 | 2023 | Azstarys |
| Livanova USA, INC. | $73.84 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $45.93 | 2025 | Jornay Pm |
| Bioxcel Therapeutics, INC. | $39.71 | 2024 | Igalmi |
| Braeburn INC. | $26.49 | 2024 | Brixadi |
| Almatica Pharma LLC | $14.00 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.